Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis

Dawood MY, M. Yusoff Dawood, M Y Dawood, Charles Obasiolu, Obasiolu CW, C W Obasiolu, Ramos J, Josefina Ramos, J Ramos, Khan-Dawood FS, F S Khan-Dawood, Firyal S. Khan‐Dawood
American journal of obstetrics and gynecology · 1997 · vol. 176(2) , pp. 387–394 · doi:10.1016/s0002-9378(97)70504-0 · PMID:9065187 · W2060638042
RCT OA: closed CC0 ⤵ 20 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the clinical, endocrine, and metabolic effects of two different doses of gestrinone in patients undergoing treatment for pelvic endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Our purpose was to determine and compare the efficacy and hormonal and metabolic effects of 1.25 mg with 2.5 mg of gestrinone given twice a week in the treatment of mild and moderate pelvic endometriosis. STUDY DESIGN: A phase II, prospective, randomized, double-blind study involving 11 patients given gestrinone 1.25 mg (five patients) or 2.5 mg (six patients) orally twice a week for 24 weeks was performed. Revised American Fertility Society scores were determined by laparoscopy before and at the end of treatment. Serum hormone (free thyroxine, free testosterone, estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone), sex hormone binding globulin, and lipid concentrations were measured before, throughout, and for 6 months after treatment. Quantitated computerized tomography of thoracic 12 through lumbar 4 vertebral bodies were determined before, at the end of, and 6 months after treatment. RESULTS: Gestrinone 2.5 mg significantly reduced the endometriosis implant score from 10.3 +/- 2.8 to 3.8 +/- 0.8 (p = 0.05). Both doses significantly reduced serum progesterone and sex hormone binding globulin levels. Estradiol, free testosterone, free thyroxine, follicle-stimulating hormone, and luteinizing hormone levels were not significantly affected. Spinal bone increased significantly by 7.1% with 2.5 mg but lost significantly by 7.1% with 1.25 mg gestrinone; these changes had not reversed completely 6 months after stopping treatment. CONCLUSIONS: In mild to moderate pelvic endometriosis 2.5 mg of gestrinone twice a week was more effective and had a more positive effect on bone mass than did 1.25 mg of gestrinone.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gestrinone Progesterone Congeners Adult Adult Double-Blind Method Double-Blind Method Drug Administration Schedule Drug Administration Schedule Endometriosis Endometriosis Endometriosis Female Female Follicle Stimulating Hormone Follicle Stimulating Hormone Follicle Stimulating Hormone Gestrinone Gestrinone Gestrinone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (26)

Cited by (21)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T22:00:10.289599+00:00
License: CC0 · commercial use OK